{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:39:31Z","timestamp":1777934371397,"version":"3.51.4"},"reference-count":11,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2019,2,19]],"date-time":"2019-02-19T00:00:00Z","timestamp":1550534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:p>Nivolumab is a fully human immunoglobulin G4 immune checkpoint inhibitor antibody approved for use in the treatment of several malignancies. Severe side effects such as Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis (SJS\/TEN) have only extremely rarely been reported with this drug. We present herein a patient who developed SJS after 16 weeks of therapy with nivolumab. A week prior to this event, he developed a pruriginous papulo-erythematous rash. Prompt recognition of this phenomenon, immune checkpoint inhibitor discontinuation and steroid therapy are necessary steps in order to avoid dismal outcomes.<\/jats:p>","DOI":"10.1177\/1078155219830166","type":"journal-article","created":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T15:02:10Z","timestamp":1550674930000},"page":"2052-2055","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":36,"title":["Late-onset Stevens\u2013Johnson syndrome due to nivolumab use for hepatocellular carcinoma"],"prefix":"10.1177","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0425-8394","authenticated-orcid":false,"given":"Constantin A","family":"Dasanu","sequence":"first","affiliation":[{"name":"Lucy Curci Cancer Center, Eisenhower Medical Center, Rancho Mirage, CA, USA"},{"name":"UC San Diego, San Diego, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2019,2,19]]},"reference":[{"key":"bibr1-1078155219830166","doi-asserted-by":"publisher","DOI":"10.7150\/jca.17144"},{"key":"bibr2-1078155219830166","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.0105"},{"key":"bibr3-1078155219830166","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.3708"},{"key":"bibr4-1078155219830166","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2872"},{"key":"bibr5-1078155219830166","doi-asserted-by":"publisher","DOI":"10.3889\/oamjms.2018.148"},{"key":"bibr6-1078155219830166","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx640"},{"key":"bibr7-1078155219830166","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000239"},{"key":"bibr8-1078155219830166","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.03.026"},{"key":"bibr9-1078155219830166","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4103\/ijd.IJD_583_17","volume":"63","author":"Kumar R","year":"2018","journal-title":"Indian J Dermatol"},{"key":"bibr10-1078155219830166","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/2327-6924.12458","volume":"29","author":"Thebeau M","year":"2017","journal-title":"J Am Assoc Nurse Pract"},{"key":"bibr11-1078155219830166","doi-asserted-by":"crossref","unstructured":"Hwang A, Iskandar A and Dasanu CA. Stevens\u2013Johnson syndrome manifesting late in the course of pembrolizumab therapy.\n                      J Oncol Pharm Pract\n                      2018 Aug 7:1078155218791314. doi: 10.1177\/1078155218791314. [Epub ahead of print].","DOI":"10.1177\/1078155218791314"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155219830166","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155219830166","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155219830166","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:20:49Z","timestamp":1777688449000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155219830166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,19]]},"references-count":11,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["10.1177\/1078155219830166"],"URL":"https:\/\/doi.org\/10.1177\/1078155219830166","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,19]]}}}